Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide ... (donanemab-azbt, 350 mg/20 mL every four weeks injection for ...

An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

Zepbound is a GLP-1 agonist containing tirzepatide ... and 3.2% (with diabetes). Starting dose: 2.5 mg weekly, increasing to 5 mg after 4 weeks. Doses may continue to increase to a maximum of 15 mg ...

from 100 mg/g to 5,000 mg/g. They were on maximally tolerated renin-angiotensin system inhibitors. Drug discontinuation was slightly higher for semaglutide (12.6%) than placebo (11.3%), mostly ...

In the trial, patients who received a once-weekly 20 mg injection of amycretin over 36 weeks saw an impressive 22% reduction in their body weight. This marks a significant achievement in the ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...

Place Zepbound, including any syringes you may need to administer the drug, in a separate bin from your other belongings. If you’re using a cold pack or travel container to store Zepbound ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

resulting in lower-than-expected revenue for the company's famous weight management drug, Zepbound. That's one of the key reasons Eli Lilly hasn't performed as well in recent months. Since many of ...